Phentermine Hydrochloride; Topiramate Patent Expiration
Phentermine Hydrochloride; Topiramate is used for managing weight in individuals with obesity or overweight-related comorbidities. It was first introduced by Vivus Llc
Phentermine Hydrochloride; Topiramate Patents
Given below is the list of patents protecting Phentermine Hydrochloride; Topiramate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Qsymia | US8580299 | Escalating dosing regimen for effecting weight loss and treating obesity | Jun 14, 2029 | Vivus Llc |
| Qsymia | US8580298 | Low dose topiramate/phentermine composition and methods of use thereof | May 15, 2029 | Vivus Llc |
| Qsymia | US8895057 | Escalating dosing regimen for effecting weight loss and treating obesity | Jun 09, 2028 | Vivus Llc |
| Qsymia | US8895058 | Low dose topiramate/phentermine composition and methods of use thereof | Jun 09, 2028 | Vivus Llc |
| Qsymia | US9011905 | Low dose topiramate/phentermine composition and methods of use thereof | Jun 09, 2028 | Vivus Llc |
| Qsymia | US9011906 | Escalating dosing regimen for effecting weight loss and treating obesity | Jun 09, 2028 | Vivus Llc |
| Qsymia | US7056890 | Combination therapy for effecting weight loss and treating obesity |
Jun 14, 2020
(Expired) | Vivus Llc |
| Qsymia | US7553818 | Combination therapy for effecting weight loss and treating obesity |
Jun 14, 2020
(Expired) | Vivus Llc |
| Qsymia | US7659256 | Combination therapy for effecting weight loss and treating obesity |
Jun 14, 2020
(Expired) | Vivus Llc |
| Qsymia | US7674776 | Combination therapy for effecting weight loss and treating obesity |
Jun 14, 2020
(Expired) | Vivus Llc |
| Qsymia | US6071537 | Anticonvulsant derivatives useful in treating obesity |
Jun 23, 2017
(Expired) | Vivus Llc |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Phentermine Hydrochloride; Topiramate's patents.
Latest Legal Activities on Phentermine Hydrochloride; Topiramate's Patents
Given below is the list recent legal activities going on the following patents of Phentermine Hydrochloride; Topiramate.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 05 Oct, 2022 | US9011905(Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 05 Oct, 2022 | US9011906(Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 11 May, 2022 | US8895058(Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 11 May, 2022 | US8895057(Litigated) |
| Expire Patent Critical | 11 Apr, 2022 | US7674776(Litigated) |
| Maintenance Fee Reminder Mailed Critical | 25 Oct, 2021 | US7674776(Litigated) |
| Expire Patent Critical | 02 Aug, 2021 | US7553818(Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 28 Apr, 2021 | US8580299(Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 28 Apr, 2021 | US8580298(Litigated) |
| Maintenance Fee Reminder Mailed Critical | 15 Feb, 2021 | US7553818(Litigated) |
Phentermine Hydrochloride; Topiramate's Family Patents
Explore Our Curated Drug Screens
Phentermine Hydrochloride; Topiramate Generic API Manufacturers
Several generic applications have been filed for Phentermine Hydrochloride; Topiramate. The first generic version for Phentermine Hydrochloride; Topiramate was by Actavis Laboratories Fl Inc and was approved on Jun 25, 2024. And the latest generic version is by Dr Reddys Laboratories Sa and was approved on Jun 12, 2025.
Given below is the list of companies who have filed for Phentermine Hydrochloride; Topiramate generic, along with the locations of their manufacturing plants worldwide.
1. ACTAVIS LABS FL INC
Actavis Laboratories Fl Inc has filed for 4 different strengths of generic version for Phentermine Hydrochloride; Topiramate. All of these versions come by the name PHENTERMINE HYDROCHLORIDE AND TOPIRAMATE. Given below are the details of the strengths of this generic introduced by Actavis Labs Fl Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 3.75MG BASE; 23MG | capsule, extended release | Prescription | ORAL | AB | Jun 25, 2024 |
| EQ 7.5MG BASE; 46MG | capsule, extended release | Prescription | ORAL | AB | Jun 25, 2024 |
| EQ 11.25MG BASE; 69MG | capsule, extended release | Prescription | ORAL | AB | Jun 25, 2024 |
| EQ 15MG BASE; 92MG | capsule, extended release | Prescription | ORAL | AB | Jun 25, 2024 |
2. DR REDDYS LABS SA
Dr Reddys Laboratories Sa has filed for 4 different strengths of generic version for Phentermine Hydrochloride; Topiramate. All of these versions come by the name PHENTERMINE HYDROCHLORIDE AND TOPIRAMATE. Given below are the details of the strengths of this generic introduced by Dr Reddys Labs Sa.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 3.75MG BASE; 23MG | capsule, extended release | Prescription | ORAL | AB | Jun 12, 2025 |
| EQ 7.5MG BASE; 46MG | capsule, extended release | Prescription | ORAL | AB | Jun 12, 2025 |
| EQ 11.25MG BASE; 69MG | capsule, extended release | Prescription | ORAL | AB | Jun 12, 2025 |
| EQ 15MG BASE; 92MG | capsule, extended release | Prescription | ORAL | AB | Jun 12, 2025 |